Halozyme (HALO) and Oruka Therapeutics (ORKA) announced that Halozyme’s wholly-owned subsidiary, Halozyme Hypercon, has entered into a global exclusive collaboration and license agreement with Oruka. Oruka has licensed Halozyme’s Hypercon technology for use with ORKA-001, in development for psoriasis and related inflammatory diseases, and up to one additional target. Hypercon is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, reducing injection volume for a given dose and supporting more convenient, patient-friendly administration. Under the terms of the agreement, Oruka will make an upfront payment to Halozyme and potential future milestone payments. Halozyme will also be eligible to receive mid-single digit royalties on net sales of products developed using the Hypercon technology.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme names Darren Snellgrove as CFO
- Halozyme Appoints New Chief Financial Officer to Drive Growth
- Halozyme price target raised to $95 from $90 at H.C. Wainwright
- Halozyme price target raised to $96 from $94 at Morgan Stanley
- Halozyme: Underappreciated, Durable Royalty-Driven Growth Beyond 2028 Supports Buy Rating